Here’s what you need to know:
1. Vitality Biopharma develops cannabinoid prodrug pharmaceuticals, used for the treatment of neurological and inflammatory disorders.
2. The corporation recently announced that it has expanded its portfolio through filing another patent application, expanding upon two previous patent applications from late 2015.
3. The new patent filing includes vanilloids, which provide pain relief through targeting the TRPV1 receptor. This receptor may play a role in visceral or abdominal pain — like inflammatory bowel disease.
4. Vitality Biopharma’s current intellectual property portfolio includes pharmaceutical prodrugs of major phytocannabinoids and endocannabinoids.
More articles on gastroenterology and endoscopy:
Elderly patients who undergo IBD surgery show high mortality, complication rates: 4 insights
SpectraScience announces accurate colorectal cancer diagnosis with WavSTAT4: 4 notes
Penn State researchers develop care plan for Crohn’s disease complications: 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
